anyone know how to keep insuline levels in check?
- Thread starter whitemogs
- Start date
squeegee
Banned
- Reaction score
- 132
The relationship between insulin resistance and hair loss is so true in any ways... so glucose is a b**ch!
Dietary vitamin D improves insulin sensitivityBy Jenny Grice23 January 2009Diabet Med 2009; 26: 19–27MedWire News: Short-term vitamin D supplementation improves a measure of postprandial insulin sensitivity in Indian men at risk for insulin resistance, study results demonstrate.
Observational studies suggest that serum levels of vitamin D may be inversely related to insulin resistance and play a role in the pathogenesis of Type 2 diabetes. Given the high prevalence of Type 2 diabetes and vitamin D deficiency in Asian Indians, the potential benefits of vitamin D supplementation merit investigation.
In a double-blind, controlled trial, Jitender Nagpal and co-workers (Sitaram Bhartia Institute of Science and Research, New Delhi, India) randomly assigned 100 male volunteers, 35 years of age or older with central obesity (waist circumference of 78 cm or more) to three oral doses of vitamin D3 (cholecalciferol, 120 000 IU each dose) or placebo every 2 weeks for 6 weeks.
Fasting insulin sensitivity (assessed by homeostasis model assessment [HOMA] and quantitative insulin sensitivity check index), postprandial insulin sensitivity (assessed by oral glucose insulin sensitivity [OGIS]) and insulin secretion (assessed by HOMA) were measured at baseline and at 6 weeks’ follow-up.
“The trial indicates that vitamin D supplementation improves postprandial insulin sensitivity in apparently healthy men likely to have insulin resistance,†state the researchers, whose results appear in the journal Diabetic Medicine.
Vitamin D supplementation resulted in an increase in the OGIS index, which was significant in the per protocol analysis, at 21.17 ml/min/kg versus a reduction of 11.43 ml/min/kg in controls. The difference was of borderline significance in the intention-to-treat analysis due to the small sample size and high drop-out rate (26%).
The greatest response was seen in men with lower baseline serum vitamin D concentrations and those with greater central adiposity. Vitamin D supplementation was not associated with any changes in fasting insulin sensitivity or insulin secretion.
The results indicate that Vitamin D supplementation may be of benefit in certain populations at high risk for Type 2 diabetes. The researchers suggest that these preliminary findings should be validated in further studies with longer follow-up.
The October, 2008 issue of the journal Diabetes published the outcome of a study of middle-aged men and women which found that lower serum vitamin D levels were associated with an increase in the risk of developing insulin resistance and elevated blood sugar over a ten year follow up period.
Researchers at the Institute of Metabolic Science in Cambridge, England followed 524 nondiabetic participants in the Ely Study, a prospective study established in 1990. Upon enrollment, the vitamin D marker serum 25-hydroxyvitamin D, serum parathyroid hormone, insulin-like growth factor-1 (IGF-1) and other factors were measured, and personal health habits such as smoking status and physical activity levels were ascertained. Weight, height, waist circumference, blood pressure, plasma glucose, lipids, and fasting insulin were measured during the initial and ten year follow-up visits.
At the end of the follow-up period, having a higher serum vitamin D level was associated with a lower adjusted ten-year risk of elevated blood sugar, insulin resistance, and high metabolic syndrome score. An association between increased IGF-1 levels and metabolic syndrome risk observed in an earlier study was not noted in the current research.
The authors remark that the study’s findings add evidence to previously reported observations concerning vitamin D’s effect on metabolic syndrome risk. Possible mechanisms of vitamin D include direct effects on pancreatic beta cell secretory function, and indirect effects involving inflammatory processes. Additionally, insufficient vitamin D can elevate serum parathyroid hormone, which is associated with a reduction in insulin sensitivity in healthy individuals.
In an accompanying editorial, Robert Scragg of the University of Auckland in New Zealand asks the question, “Are we ready for a prevention trial?†In light of the dramatically rising diabetes rates worldwide and the mounting evidence for a role of vitamin D in the prevention of the disease, well-designed clinical trials involving vitamin D supplementation are needed to confirm vitamin D’s possible protective benefits. Dr Scragg notes that the dose of vitamin D administered in these trials needs to be at least 2,000 international units per day in order to raise serum 25-hydroxyvitamin D levels above 80 nanomoles per liter, a level at which diabetes risk is lowest. “If well-designed trials are carried out and confirm a protective effect from vitamin D, it could be used by the general population as a simple and cheap solution to help prevent the diabetes epidemic,†he concludes.
Dietary vitamin D improves insulin sensitivityBy Jenny Grice23 January 2009Diabet Med 2009; 26: 19–27MedWire News: Short-term vitamin D supplementation improves a measure of postprandial insulin sensitivity in Indian men at risk for insulin resistance, study results demonstrate.
Observational studies suggest that serum levels of vitamin D may be inversely related to insulin resistance and play a role in the pathogenesis of Type 2 diabetes. Given the high prevalence of Type 2 diabetes and vitamin D deficiency in Asian Indians, the potential benefits of vitamin D supplementation merit investigation.
In a double-blind, controlled trial, Jitender Nagpal and co-workers (Sitaram Bhartia Institute of Science and Research, New Delhi, India) randomly assigned 100 male volunteers, 35 years of age or older with central obesity (waist circumference of 78 cm or more) to three oral doses of vitamin D3 (cholecalciferol, 120 000 IU each dose) or placebo every 2 weeks for 6 weeks.
Fasting insulin sensitivity (assessed by homeostasis model assessment [HOMA] and quantitative insulin sensitivity check index), postprandial insulin sensitivity (assessed by oral glucose insulin sensitivity [OGIS]) and insulin secretion (assessed by HOMA) were measured at baseline and at 6 weeks’ follow-up.
“The trial indicates that vitamin D supplementation improves postprandial insulin sensitivity in apparently healthy men likely to have insulin resistance,†state the researchers, whose results appear in the journal Diabetic Medicine.
Vitamin D supplementation resulted in an increase in the OGIS index, which was significant in the per protocol analysis, at 21.17 ml/min/kg versus a reduction of 11.43 ml/min/kg in controls. The difference was of borderline significance in the intention-to-treat analysis due to the small sample size and high drop-out rate (26%).
The greatest response was seen in men with lower baseline serum vitamin D concentrations and those with greater central adiposity. Vitamin D supplementation was not associated with any changes in fasting insulin sensitivity or insulin secretion.
The results indicate that Vitamin D supplementation may be of benefit in certain populations at high risk for Type 2 diabetes. The researchers suggest that these preliminary findings should be validated in further studies with longer follow-up.
The October, 2008 issue of the journal Diabetes published the outcome of a study of middle-aged men and women which found that lower serum vitamin D levels were associated with an increase in the risk of developing insulin resistance and elevated blood sugar over a ten year follow up period.
Researchers at the Institute of Metabolic Science in Cambridge, England followed 524 nondiabetic participants in the Ely Study, a prospective study established in 1990. Upon enrollment, the vitamin D marker serum 25-hydroxyvitamin D, serum parathyroid hormone, insulin-like growth factor-1 (IGF-1) and other factors were measured, and personal health habits such as smoking status and physical activity levels were ascertained. Weight, height, waist circumference, blood pressure, plasma glucose, lipids, and fasting insulin were measured during the initial and ten year follow-up visits.
At the end of the follow-up period, having a higher serum vitamin D level was associated with a lower adjusted ten-year risk of elevated blood sugar, insulin resistance, and high metabolic syndrome score. An association between increased IGF-1 levels and metabolic syndrome risk observed in an earlier study was not noted in the current research.
The authors remark that the study’s findings add evidence to previously reported observations concerning vitamin D’s effect on metabolic syndrome risk. Possible mechanisms of vitamin D include direct effects on pancreatic beta cell secretory function, and indirect effects involving inflammatory processes. Additionally, insufficient vitamin D can elevate serum parathyroid hormone, which is associated with a reduction in insulin sensitivity in healthy individuals.
In an accompanying editorial, Robert Scragg of the University of Auckland in New Zealand asks the question, “Are we ready for a prevention trial?†In light of the dramatically rising diabetes rates worldwide and the mounting evidence for a role of vitamin D in the prevention of the disease, well-designed clinical trials involving vitamin D supplementation are needed to confirm vitamin D’s possible protective benefits. Dr Scragg notes that the dose of vitamin D administered in these trials needs to be at least 2,000 international units per day in order to raise serum 25-hydroxyvitamin D levels above 80 nanomoles per liter, a level at which diabetes risk is lowest. “If well-designed trials are carried out and confirm a protective effect from vitamin D, it could be used by the general population as a simple and cheap solution to help prevent the diabetes epidemic,†he concludes.